Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...

Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as ...

FDA seizes hundreds of fake Ozempic units from US supply after Novo Nordisk alerts regulators to counterfeit semaglutide ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Reviewing the bioequivalence study of the antidiabetic drug Semaglutide of MSN Laboratories, the Subject Expert Committee ...

The following is a summary of “Oral semaglutide for the treatment of obesity: a retrospective real-world study,” published in ...

Drug major Cipla has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...

Ozempic’s active ingredient is semaglutide, which belongs to a class of medications called incretin mimetics, and was approved as a treatment for type 2 diabetes via a 1-milligram injection in 2017.